complete data, 21 of 56 placebo-treated patients and 24 of 61 rituximab-treated patients achieved the primary end point. After multiple imputation of missing outcomes, response rates in the placebo and rituximab groups were 36.8% and 39.8%, respectively (adjusted odds ratio 1.13 [95% confidence interval 0.50, 2.55]). There were no significant improvements in any outcome measure except for unstimulated salivary flow. The mean 6 SD costs per patient for rituximab and placebo were £10,752 6 264.75 and £2,672 6 241.71, respectively. There were slightly more adverse events (AEs) reported in total for rituximab, but there was no difference in serious AEs (10 in each group).
Conclusion. The results of this study indicate that rituximab is neither clinically effective nor costeffective in this patient population.
Primary Sj€ ogren's syndrome (SS) is the second most common autoimmune rheumatic disease after rheumatoid arthritis (RA) (1) . Patients with primary SS are typically women (9:1 female:male ratio), and the prevalence of the disease is estimated to be 1-6 per 1,000 adult women. Typical symptoms of primary SS are oral and ocular dryness, fatigue, and pain. Fibromyalgia is also reported in 5% of patients with primary SS, comparable to its frequency in systemic lupus erythematosus (2) . Organspecific systemic involvement is observed in 5-20% of patients and includes cutaneous involvement, peripheral neuropathy, nonerosive arthritis, interstitial cystitis, and lung and renal disease. Patients with primary SS almost always have evidence of B cell hyperreactivity, with antiRo/anti-La antibodies and hypergammaglobulinemia.
Currently, treatment of primary SS focuses on relieving symptoms rather than altering the course of the disease. For ocular dryness, artificial tears are reasonably effective. For oral dryness, however, symptomatic therapies (sprays, lozenges, pastilles) have limited efficacy. Pilocarpine has been shown to alleviate symptoms of dryness (3, 4) . However, the usefulness of pilocarpine is generally considered to be limited, and its side effects reduce the risk/benefit profile. There is no effective therapy for fatigue.
In the absence of positive clinical trial data, treatment of systemic primary SS is empirical. Hydroxychloroquine and/or low-dose prednisolone are often used in mild disease (although recent findings from the Randomized Evaluation of Hydroxychloroquine in Primary Sj€ ogren's Syndrome study suggest limited benefit [5] ). For severe disease, such as progressive neuropathy, intravenous (IV) methylprednisolone, cyclophosphamide, azathioprine, cyclosporine, mycophenolate mofetil, or chlorambucil may be used. In B cell lymphoma, it is routine to treat with combination chemotherapy plus rituximab.
Rituximab is a monoclonal antibody against CD20 (a cell surface antigen expressed on B cells). Treatment with rituximab induces a rapid and sustained depletion of B cells. Rituximab is currently approved for the treatment of relapsed or refractory non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and in combination with methotrexate for the treatment of RA.
Evidence from small prospective, uncontrolled, open-label studies of rituximab in primary SS has shown improvements in patient-reported levels of dryness, pain, fatigue, and disease activity (patient's global assessment) as well as improvements in Short Form 36 (SF-36) health survey scores (6,7), stimulated salivary flow (8) , and physician's global assessment of disease activity (9) . A prospective study comparing symptom levels over 120 weeks of follow-up between patients receiving rituximab in one hospital and disease-modifying antirheumatic drugs (DMARDs) in another showed superior improvements for rituximab compared to DMARD therapy (10) .
Findings from small double-blind, randomized, placebo-controlled trials have also provided some cause for optimism in terms of reduced fatigue (11) and improvements in ocular dryness (12) . More recently, however, in the Tolerance and Efficacy of Rituximab in Primary Sj€ ogren's Syndrome (TEARS) study (13) , there was no significant difference in the proportions of patients achieving the primary end point (absolute improvement of $30 mm on 2 of 4 visual analog scales [VAS] measuring fatigue, dryness, pain, and patient's global assessment of disease activity) at 24 weeks, although a greater response in terms of fatigue was demonstrated at earlier time points.
As evidence from randomized trials has only addressed the efficacy of a single course of rituximab, we are still missing the clinical knowledge that could be obtained from a randomized, double-blind evaluation of a follow-up dose of rituximab in patients with primary SS. The Trial of Anti-B cell Therapy in Patients with Primary Sj€ ogren's Syndrome (TRACTISS) was designed to determine the effectiveness of rituximab in improving symptoms of fatigue or oral dryness in patients with primary SS following 2 courses of therapy. The TRACTISS protocol has been reported (14) . Briefly, between August 2011 and January 2014, participants were recruited from 25 UK rheumatology clinics and were eligible if they had primary SS, were ages 18-80 years, were positive for anti-Ro autoantibodies, and had some (greater than zero) unstimulated salivary flow, symptomatic fatigue, and oral dryness worse than 5 of 10 on a self-completed Likert scale. Eligible participants had to be receiving a stable dose of corticosteroids, nonsteroidal antiinflammatory drugs, DMARDs, pilocarpine, and antidepressants for 4 weeks prior to and throughout the study, and they had to provide written informed consent to participate. Exclusion criteria included secondary SS, hepatitis B or C infection, tuberculosis, HIV infection or other immunodeficiency, prior use of rituximab or a monoclonal antibody, malignancies within the previous 5 years, recent organ transplant, major surgery either planned or within the previous 3 months, pregnancy/lactation, and unwillingness to use contraception throughout the study. Eligibility criteria were changed after the 37th randomization to reduce the required period of stable hydroxychloroquine use (where applicable) from 6 months to 4 weeks and to allow patients with benign ethnic neutropenia to take part rather than being excluded due to neutropenia. There was no difference in characteristics between patients randomized before and those randomized after this change.
PATIENTS AND METHODS
Intervention and outcome measures. Rituximab was provided free of charge to the study by Hoffmann-La Roche. Participants received either intravenous (IV) rituximab (1,000 mg in 250 ml saline) or IV placebo (250 ml saline) in 2 courses at weeks 0, 2, 24, and 26. To reduce risk of infusion reactions, patients received methylprednisolone, acetaminophen, and chlorpheniramine preinfusion and oral prednisolone postinfusion, tapering from 60 mg/day to 15 mg/day over 7 days postinfusion (14) .
At baseline and at weeks 16, 24, 36, and 48, patients completed VAS questionnaires recording fatigue, overall dryness, oral dryness, ocular dryness, pain, and disease activity (global assessment) (average symptom level over previous 2 weeks: 0 5 none, 100 mm 5 severe), as well as the European League Against Rheumatism (EULAR) Sj€ ogren's Syndrome Patient Reported Index (ESSPRI) (15) . The Profile of Fatigue and Discomfort Sicca Symptoms Inventory (PROFAD-SSI) (16), SF-36, and EuroQol 5-domain 3L (EQ-5D-3L) (17) questionnaires were completed at baseline and at weeks 24 and 48. Unstimulated and stimulated (using 2% citric acid solution) salivary flow was measured at these visits, as was lacrimal flow using the Schirmer I test. Physicians completed the EULAR Sj€ ogren's Syndrome Disease Activity Index (ESSDAI) (18) and global assessment of disease activity at all visits, and they completed the Sj€ ogren's Syndrome Disease Activity Index (19) , Sj€ ogren's Syndrome Damage Index (20) , Sj€ ogren's Syndrome Disease Damage Index (19) , Sj€ ogren's Syndrome Clinical Activity Index (21) , and global assessment of damage at baseline and at weeks 24 and 48 (14) .
Randomization and blinding. Randomization was by 24-hour central telephone service operated by the Clinical Trials Research Unit. Consenting participants were registered before undergoing further clinical tests to ensure eligibility. Once eligibility was confirmed, participants were allocated by minimization, which assigned a patient with 80% probability to the arm that reduced the between-group imbalance in randomizing center, age category, years since diagnosis, consent for ultrasound, and consent for biopsy substudies.
Each site's dispensing pharmacy received details of the participant allocation, by fax, to facilitate infusion preparation. On the day of infusion, the pharmacy provided either a bag of pure saline (placebo) or a bag of saline to which rituximab had been added. A small volume of saline was withdrawn from bags containing rituximab to ensure that no difference in bag volume was detected. Placebo and rituximab infusion bags were otherwise identical.
Sample size. The predefined minimum clinically important effect of rituximab was an increase in treatment response rate from 20% in the placebo arm to 50% in the rituximab arm. For a 2-sided continuity-corrected chi-square test, 50 patients with complete data in each treatment arm were needed in order to have 80% power to detect this difference at a 5% significance level. To allow for noncompletion, 110 patients (55 per treatment arm) were needed. In July 2013, the Data Monitoring and Ethics Committee recommended extending recruitment until the end of the planned recruitment period and, to reduce loss to follow-up, a protocol amendment allowed participants to complete the final primary end point questionnaire at home rather than attending clinic.
Statistical analysis. The primary end point was the achievement of a reduction of at least 30% relative to the baseline measurement in the patient-completed VAS assessments of either fatigue or oral dryness at week 48. Secondary end points included the patient-completed and physician-completed assessments at other time points and measurements of salivary and lacrimal flow. The primary end point was modeled using mixed-effects logistic regression, with a fixed effect for the randomized treatment arm and terms for the minimization factors (age category, disease duration category, and consent for substudies as fixed effects and randomizing center as a random effect). All patients were included in this primary analysis, even if the patient had incomplete outcome data. For patients with incomplete primary end point questionnaire data (fatigue and oral dryness each at baseline and week 48), we used multiple imputation by chained equations (22) to impute plausible missing VAS values; the imputation function included fixed randomization factors (for baseline values) and also the baseline values (for week 48 values). Missing values were imputed separately for each scale, both for placebo-treated patients and for rituximab-treated patients, to produce 1 full data set. This was repeated n times, where n is the number of patients with incomplete data. Analysis was performed for each data set, and the results were combined to estimate treatment effects and appropriate 95% confidence intervals (95% CIs) using Rubin's rules (23) .
To assess sensitivity of results to alternative assumptions about missing data, we repeated the analysis using a last observation carried forward approach, a complete-case analysis, and a per-protocol population analysis. In order to calculate adjusted absolute differences in response rates, we fitted a linear probability model (binary error structure with identity link function); we excluded the random center effect from this model to ensure model convergence.
Secondary end points were analyzed by fitting a randomcoefficients mixed-effects linear regression model, with fixed effects for baseline value, age, disease duration, the substudy consent, time, and time-by-treatment interaction, and random effects for patient and patient-by-time interaction, taking the time to be the number of weeks since randomization. Most end points were analyzed on their original scale, although we logtransformed the salivary and lacrimal flow rates and the ESSDAI score (including an offset to avoid zero values) to better approximate normality. We repeated this longitudinal analysis using a covariance pattern type mixed model, treating assessments as discrete sequential observations (relaxing the assumption of a linear treatment effect) so as to provide graphical summaries of group means at each time point using least squares means. Adverse event (AE) data were reported throughout the trial duration and collated after completion of follow-up at 48 weeks.
Economic analyses. An economic evaluation was conducted alongside the clinical trial to assess the cost-effectiveness of rituximab compared to placebo over 48 weeks. Incremental cost-effectiveness ratios were calculated and assessed against a willingness-to-pay threshold of £20,000 per quality-adjusted lifeyear (QALY) gain (24) . QALYs were calculated using utility weights derived from the EQ-5D-3L collected 16, 24, 36, and 48 weeks postrandomization (17) . Resource use was captured using bespoke patient-completed forms and nurse records of medications and hospital visits. Costs were attached to individuals by using NHS reference costs and Personal Social Services Research Unit and British National Formulary databases (price year 2014) (25) (26) (27) . Analyses were conducted from the perspective of the health care provider. The probability of cost-effectiveness was determined by bootstrapping and constructing cost-effectiveness acceptability curves using a range of willingness-to-pay thresholds for QALY gains (28) . Multiple imputation was used to account for missing cost and EQ-5D data (29) . No discounting was undertaken due to the short follow-up duration of 48 weeks per patient. Table 1 .
Primary end point analysis. All 66 placebotreated patients and 67 rituximab-treated patients were included in the primary end point analysis. Sixteen participants (12.0%) had incomplete fatigue or oral dryness measurements at baseline (1 in each group) or at week 48 (9 in the placebo group and 5 in the rituximab group). The primary end point response rates among patients with complete data were 37.5% for placebo-treated patients (21 of 56) and 39.3% for rituximab-treated patients (24 of 61). After multiple imputation of missing responses, the mean response rates were 36.8% and 39.8% for the placebo and rituximab treatment arms, respectively (unadjusted absolute . In the primary analysis, rituximab-treated patients were not significantly more likely than placebo-treated patients to achieve 30% reduction in fatigue or oral dryness (odds ratio [OR] 1.13 [95% CI 0.50, 2.55], P 5 0.76). The baseline-adjusted absolute difference in response rates (rituximab -placebo) was 1.7% (95% CI 216.5, 19.1) (P 5 0.84). The lack of significant treatment effect remained even when using different end point imputation strategies or a complete-case analysis. A per-protocol population analysis (excluding patients found to be ineligible, those not receiving all 4 doses within a reasonable time frame, and those with incomplete primary end point data) also did not yield significant results (OR 0.9 [95% CI 0.1, 6.5], P 5 0.95).
Secondary end points. Longitudinal analyses of patient VAS values did not reveal significant differences in change over time between randomized treatment arms for any of the 6 VAS scores. Figures 2A and B illustrate the levels of symptomatic fatigue and oral dryness reported over time; there were no significant differences between the groups at any time point for these or any of the other symptom scales (see Supplementary Figure B1 , http://onlinelibrary.wiley.com/doi/10.1002/art. 40093/abstract).
Composite disease activity scores and patientreported outcome measures showed no benefit conferred by rituximab. There was no significant difference between the 2 groups over time in average ESSPRI or ESSDAI scores (except for a small relative difference in ESSDAI scores at week 36 in favor of rituximab) ( Table 2) (also  see Supplementary Tables C1-C12 , http://onlinelibrary. wiley.com/doi/10.1002/art.40093/abstract). There was no improvement conferred by rituximab in any domain of the SF-36 or in the SF-36 component scores. There was also no improvement conferred by rituximab in the PROFAD-SSI domains at any time point. We did observe a difference between treatment arms in unstimulated salivary flow. Over the duration of follow-up, we found that the log-transformed unstimulated salivary flow values seemed to hold constant for rituximabtreated patients and to deteriorate for placebo-treated patients. Although the treatment-by-time interaction effect was not statistically significant at traditional thresholds (estimate 0.013 [95% CI 20.001, 0.028], P 5 0.066), the between-group differences between the mean values of unstimulated salivary flow at weeks 36 and 48 were statistically significant (Table 2 and Figure 2C ). No similar benefit was seen in stimulated salivary flow or in mean lacrimal flow ( Figure 2D ).
We performed 4 post hoc subgroup analyses to investigate treatment modification effect due to baseline ESSDAI scores (using 2 different thresholds), baseline ESSPRI scores, and disease duration since diagnosis (Table 3) . No significant treatment modification effect was observed in any of these subgroup analyses.
Cost-effectiveness. The mean costs and QALY estimates by treatment arm at 48 weeks are included in Supplementary Table D1 , http://onlinelibrary.wiley.com/ doi/10.1002/art.40093/abstract. When we excluded the rituximab infusion, no significant difference was observed in resource use between treatment arms. However, including the rituximab infusion conferred significant differences in costs between treatment arms. The mean 6 SD cost per patient in the rituximab arm was £10,752 6 264.75, compared to £2,672 6 241.71 in the placebo arm. Mean 6 SD QALYs were 0.55 6 0.003 and 0.56 6 0.004 in the rituximab and placebo groups, respectively. The higher mean costs and lower QALYs mean that placebo dominates rituximab (see Supplementary Figure  D1 , http://onlinelibrary.wiley.com/doi/10.1002/art.40093/ abstract). Bootstrapping the mean costs and QALYs suggested that rituximab had a 0% probability of being cost-effective at any threshold from £0 to £200,000.
Safety. Rituximab was well-tolerated among patients. There were no deaths in either treatment arm. There were 10 serious AEs (SAEs) among 9 patients in each treatment arm, of which 3 events in 3 patients in each treatment arm were serious adverse reactions (Table 4) . One participant randomized to receive rituximab did not receive any rituximab prior to having an SAE. One serious infusion reaction was reported in 1 patient receiving rituximab, and 1 serious anaphylaxis event was reported in 1 patient receiving placebo. For nonserious AEs, 275 were reported in 55 placebo-treated patients, of which 61 (22.2%) were suspected to be related to treatment, 24 (8.7%) resulted in delayed or modified treatment administration, and 5 (1.8%) resulted in cessation of treatment; 325 nonserious AEs were reported in 61 rituximabtreated patients, of which 82 (25.2%) were suspected to be related to treatment, 33 (10.2%) resulted in delayed or modified treatment administration, and 10 (3.1%) resulted in cessation of treatment. § Raw values were highly positively skewed; therefore, they were log-transformed prior to analysis, and the results were back-transformed for presentation. Treatment effects presented for these comparisons are ratios on the original scale rather than differences on the logarithmic scale. ¶ By Schirmer I test.
DISCUSSION
TRACTISS is the largest randomized, placebocontrolled trial of rituximab in patients with primary SS to date. After 2 courses of treatment, each comprising 2 doses of 1,000 mg of rituximab, patients were not significantly more likely to report a response to treatment at the 48-week time point (in terms of a reduction of 30% of baseline measurement in either oral dryness or fatigue on a VAS questionnaire) than those randomized to receive placebo. These and other patient-reported outcomes of ocular and overall dryness, joint pain, and global assessment of disease activity were not significantly improved by rituximab at any time point. We also did not observe a significant benefit in terms of lacrimal flow or in any of the composite patient-reported outcomes or disease activity indices, except for a one-off significant difference between groups in the ESSDAI score at week 36. We did observe significant differences between the groups in average unstimulated salivary flow rates; rituximab-treated patients maintained their baseline flow rate, while the rate decreased in placebo-treated patients. However, given the many statistical tests performed in these secondary outcome analyses, this may well be a Type I error and should not be overinterpreted. No difference in the safety profile was observed between the 2 treatment arms.
In the economic analyses, a small nonsignificant difference in QALYs was observed between treatment arms in favor of placebo. The main driver of costs was the rituximab infusion, which incurred a cost of £1,746 per 1,000 mg and a significantly higher overall cost compared to placebo. There was no significant difference in costs when rituximab was excluded. Further analysis revealed that even at a willingness-to-pay threshold 10 times higher than the current recommendation of the National Institute for Health and Care Excellence (24), rituximab was not cost-effective; even with a relatively large reduction in price the use of rituximab is unlikely to be cost-effective.
TRACTISS is the fourth double-blind, placebocontrolled, randomized trial of rituximab in primary SS reported to date, bringing the total number of patients included in such studies to 302. The first study, a pilot randomized controlled trial (RCT) in 17 patients (11), showed a greater reduction in fatigue among patients randomized to receive rituximab compared to those receiving placebo, but showed no significant difference in the proportions of patients achieving either a 20% or a 30% reduction from baseline in fatigue at 6 months. A later RCT in 30 patients (12) showed significant changes from baseline for most variables (including salivary flow rates and patientreported measures of fatigue and oral and ocular dryness) in both treatment arms, but the 20 rituximab-treated patients differed significantly from the 10 placebo-treated patients in only stimulated salivary flow at 12 weeks and ocular dryness at 36 and 48 weeks.
Most recently, the TEARS study (13) analyzed 120 patients randomized to receive either rituximab or placebo in a multicenter trial and did not reveal a significant difference in numbers of patients achieving the primary end point (reductions of 30 mm on at least 2 VAS for dryness, pain, fatigue, and global assessment of disease activity). Although a significant response was detected at 6 weeks, particularly in fatigue, this was not sustained by the 24-week time point. Signs of efficacy in fatigue and dryness were evident when these outcome data were analyzed longitudinally, but symptoms of pain and globally assessed disease activity were not significantly improved. As in previous studies, the TEARS study showed no significant difference in safety profiles between the treatment arms.
The TRACTISS trial differed from these randomized trials in that patients were randomized to receive 2 doses of the trial drug in a double-blinded manner. It was hoped that signals of efficacy observed in earlier studies would be seen at the same time points in the TRACTISS trial, and that a second dose would demonstrate long-term efficacy of rituximab. However, early efficacy measured by fatigue at 16 weeks (the TEARS study) and late efficacy in terms of ocular dryness (Meijer et al [12] ) were not observed in the TRACTISS trial. Similarly, although we observed significant deterioration in unstimulated salivary flow with placebo compared to rituximab at later time points, no such effect was reported from other RCTs.
Early evidence from nonrandomized trials and uncontrolled studies was more promising. In an open-label prospective study (10) , 19 patients at one center received rituximab and 22 patients at another center received DMARD therapy with follow-up over 120 weeks. Patients in that study had higher disease activity (mean baseline ESSDAI score of 20). Significant differences between the 2 treatment arms were demonstrated in fatigue and dryness VAS scores (mean 6 SEM fatigue score 51.8 6 4.5 in the DMARD group versus 41.1 6 4.2 in the rituximab group at week 120; mean 6 SEM dryness score 51.8 6 11.1 in the DMARD group versus 25.1 6 7.7 in the rituximab group at week 120) as well as in the ESSDAI score (8.8 6 1.7 in the DMARD group versus 5.2 6 0.9 in the rituximab group at week 120), unstimulated salivary flow (0.1 6 0.08 in the DMARD group versus 0.4 6 0.04 in the rituximab group at week 120), and lacrimal flow (5.5 6 0.8 in the DMARD group versus 7.3 6 0.8 in the rituximab group at week 120). However, bias due to potential differences between practices at the centers, the open-label nature of one study, and the differing additional study medications (DMARDs and prednisone versus methylprednisolone, acetaminophen, and chlorpheniramine) cannot be ruled out. Sixteen patients who received rituximab in an uncontrolled study (30) showed significant improvements from baseline in SF-36 component scores (mean physical and mental component summary score improvements of 16.9 and 31.2, respectively), but no such improvement was found either in our study (Table 2 ) or in the TEARS study.
Researchers have previously suggested (5,13) that outcome measures used in studies of these patients are not sufficiently sensitive to changes in the patient's condition after successful treatment. To that end, composite outcome measures to be completed by the physician (18) and by the patient (15) were developed by EULAR. These outcome measures were developed in patient populations of an age similar to those in the TEARS study and TRACTISS trial, but the development population profiles for both tools involved patients with slightly longer disease durations (;8.5 years) than seen here. Moerman et al computed ESSDAI scores for all patients in one RCT (31) and concluded that the ESSDAI was sensitive enough to detect a treatment effect of rituximab despite low average ESSDAI scores. In both the TEARS study and the TRACTISS trial, patients had low ESSDAI scores at baseline (relative to the maximum score of 123), and mean improvement in ESSDAI score was not different between the 2 treatment arms. The ESSPRI did not have the same problem as the ESSDAI in the TRACTISS trial, but no significant difference was detected overall, nor did the ESSPRI define a subgroup that demonstrated a benefit. A recent reanalysis of data from the TEARS study (32) proposed a data-driven composite outcome measure, the Sj€ ogren's Syndrome Responder Index (SSRI), rooted in the assumption that rituximab is effective. Data from the TRACTISS trial may assist in the external validation of the SSRI.
A post hoc analysis of data from the TEARS study (33) to estimate the required sample size to detect a significant difference in response rates suggested that the most sensitive end point by which response to treatment can be assessed would be change in ultrasound grading. However, the observed improvement on ultrasonography in the TEARS study (34) did not translate into patient-reported symptomatic improvement. Findings of the TRACTISS ultrasound substudy will be presented at a later date, as will results of the labial gland biopsy substudy.
Despite the requirement for a minimum level of symptomatic fatigue and oral dryness in order to take part in the TRACTISS trial, the patients mostly had disease of recent onset and had mild systemic disease activity as measured by the ESSDAI. Although the 2 courses of rituximab given constituted a treatment regimen different from the single course in other RCTs, it remains a possibility that a benefit to patients would be seen if rituximab is administered over longer periods of time, such as those seen in longer open-label comparative studies. Further, although TRACTISS is the largest trial of rituximab in primary SS to date, a sample size of 133 patients is small by the standards of phase III randomized trials, and confidence intervals around our estimates were wide. The low population prevalence of primary SS poses challenges to recruitment and emphasizes the importance of patient retention to ensure that studies are adequately powered.
Despite our ambition of performing a metaanalysis with data from the TEARS study, our study omitted a 6-week assessment visit, which was the time point at which the greatest fatigue response was observed in the TEARS study. We omitted this visit to reduce the burden on patients. Although our study had low levels of patient withdrawal (and used multiple imputation to account for uncertainty due to incomplete data), it was necessary to offer to mail questionnaires to some participants to capture primary end point data at 48 weeks.
Like the TEARS study, the TRACTISS trial was designed to have power to detect a large difference in response rates between treatment arms; the possible side effects due to rituximab as well as the underlying inconvenience and costs of rituximab administration mean that a large benefit would need to be demonstrated for rituximab to be worthwhile. The existence of a smaller long-term effect cannot be ruled out-and may be identified in a possible meta-analysis-but it remains to be seen whether a smaller effect would be worthwhile or cost-effective. Moreover, in common with other studies in this context, many outcome measurements were compared at several time points, and we did not adjust our secondary end point analyses for multiple comparisons; it is possible that the relative deterioration in unstimulated salivary flow in placebo-treated patients was a false-positive finding.
Although there did not appear to be any excess risk due to rituximab, the results of the TRACTISS trial do not support the general use of rituximab in treating primary SS, particularly in patients with recent disease onset and/or low disease activity. Meta-analysis with the TEARS study may improve overall precision of findings, but it seems unlikely that the combined results will identify a worthwhile treatment benefit. The need for further large randomized trials to demonstrate longer-term benefit appears questionable, since the lack of effect of 2 courses of rituximab seems consistent with the lack of benefit of 1 course in randomized trials. Rituximab may still have a role in treating patients with primary SS who have high levels of systemic disease activity and whose disease has failed to improve following conventional immunosuppressive therapy.
